Skip to main content

Table 5 Use of resources and total cost

From: Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care

Groups

Inadequate response

Remission

Total

P value

Number of patients, %

N = 965 (42.7%)

N = 1,295 (57.3%)

N = 2,260 (100%)

Use of resources

    

Medical visits

16.8 (9.1)

11.1 (8.2)

13.6 (8.9)

<0.001

Laboratory tests:

0.6 (0.8)

0.5 (0.7)

0.5 (0.8)

<0.001

Supplemental tests

0.1 (0.4)

0.1 (0.3)

0.1 (0.3)

NS

Referrals

0.2 (0.4)

0.1 (0.4)

0.2 (0.4)

0.005

Work productivity losses (days)

20.2 (63.7)

12.8 (45.5)

16.1 (54.2)

0.001

Uncorrected cost model (Euros)

    

- Healthcare costs

857.2

443.2

620.0

<0.001

Medical visits

383.9

253.7

309.3

<0.001

Laboratory tests:

15.0

10.3

12.3

<0.001

Supplemental tests

4.3

2.2

3.1

<0.001

Drugs

453.9

177.1

295.3

<0.001

- Non-healthcare costs (productivity)

1,615.3

1,021.5

1,275.1

0.001

Total cost

2,472.5

1,464.8

1,895.0

<0.001

Corrected cost model (Euros)*

  

Difference

 

Healthcare costs

826.1

451.2

374.85

<0.001

95% CI

798.5 - 853.5

428.8 - 473.6

  

Non-healthcare costs (productivity)

1,842.0

991.4

850.64

<0.001

95% CI

1,525.7 - 2,158.3

733.6 - 1249.1

  

Total cost

2,668.1

1,442.6

1,225.49

<0.001

95% CI

2,346.9 - 2,989.2

1,180.9 - 1,704.2

  
  1. Values are given as mean (standard deviation); p: statistical significance; CI: confidence interval; Referrals were not considered in the calculation of health costs.
  2. (*) ANCOVA model: each F test contrasts the simple effect of the presence of remission on each combination of levels of the other effects shown. These tests are based on pairwise, linearly independent comparisons between the estimated marginal means. Random components: remission status and sex; covariates: comorbidity and age.